Literature DB >> 20603743

Implications of hepatitis C virus infection for behavioral symptoms and activities of daily living.

Carolina Posada1, David J Moore, Steven Paul Woods, Ofilio Vigil, Chris Ake, William Perry, Tarek I Hassanein, Scott L Letendre, Igor Grant.   

Abstract

Hepatitis C virus (HCV) is neurovirulent and has been shown to be associated with neuropsychological (NP) deficits in a subset of infected individuals. Despite these previous findings, little work has been done to examine neurobehavioral symptoms associated with HCV infection. We examined 34 HCV seropositive (HCV+) individuals and 35 healthy comparison participants (HCV-) with the self-rating form of the Frontal Systems Behavior Scale (FrSBe). Results showed that at the group level, only the FrSBe apathy subscale mean was clinically elevated (T score >65) among HCV+ persons; executive dysfunction, disinhibition, and total subscale means were not clinically elevated. At the individual level, a significantly higher proportion of HCV+ individuals than of HCV- individuals reported clinically elevated FrSBe T scores . Moreover, HCV+ individuals were nearly 3 times as likely to report clinically elevated FrSBe T scores of apathy, executive dysfunction, and disinhibition as compared to HCV- participants. A multiple regression that included substance use disorders, neuropsychological impairment, and age indicated that HCV status was an independent predictor of self-reported FrSBe total T scores. Across all participants, small, yet significant, correlations were found between elevated self-reported FrsBe T scores and dependence in activities of daily living. These results show that a subset of HCV-infected individuals report clinically elevated behavioral symptoms. Clinical implications for the assessment and management of elevated behavioral symptoms in HCV are discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20603743      PMCID: PMC2898888          DOI: 10.1080/13803390903418900

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  31 in total

Review 1.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

2.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

3.  Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.

Authors:  Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

4.  Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.

Authors:  Herbert L Bonkovsky; Kristin K Snow; Peter F Malet; Carla Back-Madruga; Robert J Fontana; Richard K Sterling; Clark C Kulig; Adrian M Di Bisceglie; Timothy R Morgan; Jules L Dienstag; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

5.  Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis.

Authors:  Linas A Bieliauskas; Carla Back-Madruga; Karen L Lindsay; Kristin K Snow; Ziad Kronfol; Anna S Lok; Latha Padmanabhan; Robert J Fontana
Journal:  J Clin Exp Neuropsychol       Date:  2006-11       Impact factor: 2.475

6.  Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C.

Authors:  K B Hussain; R J Fontana; C A Moyer; G L Su; N Sneed-Pee; A S Lok
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

7.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

8.  Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function.

Authors:  Dawn I Velligan; Janice L Ritch; Dawen Sui; Margaret DiCocco; Cindy D Huntzinger
Journal:  Psychiatry Res       Date:  2002-12-30       Impact factor: 3.222

9.  Self-reported executive dysfunction, neuropsychological impairment, and functional outcomes in multiple sclerosis.

Authors:  Michael R Basso; Isaac S Shields; Natasha Lowery; Courtney Ghormley; Dennis Combs; Peter A Arnett; Jay Johnson
Journal:  J Clin Exp Neuropsychol       Date:  2008-11       Impact factor: 2.475

10.  Neuropsychiatric impact of hepatitis C on advanced HIV.

Authors:  E L Ryan; S Morgello; K Isaacs; M Naseer; P Gerits
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

View more
  10 in total

1.  Cognitive reserve protects against apathy in individuals with human immunodeficiency virus.

Authors:  Miriam E Shapiro; Jeannette R Mahoney; Deena Peyser; Barry S Zingman; Joe Verghese
Journal:  Arch Clin Neuropsychol       Date:  2013-09-09       Impact factor: 2.813

2.  Intra-individual variability across neurocognitive domains in chronic hepatitis C infection: elevated dispersion is associated with serostatus and unemployment risk.

Authors:  Erin E Morgan; Steven Paul Woods; Alexandra Rooney; William Perry; Igor Grant; Scott L Letendre
Journal:  Clin Neuropsychol       Date:  2012-04-26       Impact factor: 3.535

3.  Implications of apathy for everyday functioning outcomes in persons living with HIV infection.

Authors:  Rujvi Kamat; Steven Paul Woods; Thomas D Marcotte; Ronald J Ellis; Igor Grant
Journal:  Arch Clin Neuropsychol       Date:  2012-06-15       Impact factor: 2.813

4.  Depression and Apathy Among People Living with HIV: Implications for Treatment of HIV Associated Neurocognitive Disorders.

Authors:  Vaughn E Bryant; Nicole E Whitehead; Larry E Burrell; Vonetta M Dotson; Robert L Cook; Paul Malloy; Kathryn Devlin; Ronald A Cohen
Journal:  AIDS Behav       Date:  2015-08

5.  Incident major depressive episodes increase the severity and risk of apathy in HIV infection.

Authors:  Rujvi Kamat; Jordan E Cattie; Thomas D Marcotte; Steven Paul Woods; Donald R Franklin; Stephanie H Corkran; Ronald J Ellis; Igor Grant; Robert K Heaton
Journal:  J Affect Disord       Date:  2015-01-19       Impact factor: 4.839

6.  Association of HIV serostatus and metabolic syndrome with neurobehavioral disturbances.

Authors:  Caitlin N Pope; Jessica L Montoya; Elizabeth Vasquez; Josué Pérez-Santiago; Ronald Ellis; J Allen McCutchan; Dilip V Jeste; David J Moore; María J Marquine
Journal:  J Neurovirol       Date:  2020-07-30       Impact factor: 2.643

7.  Elevated neurobehavioral symptoms are associated with everyday functioning problems in chronic methamphetamine users.

Authors:  Jordan E Cattie; Steven Paul Woods; Jennifer E Iudicello; Carolina Posada; Igor Grant
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

8.  Functional MRI and delay discounting in patients infected with hepatitis C.

Authors:  Holly McCready; Milky Kohno; Michael Kolessar; Laura Dennis; Daniel Kriz; Hannah Luber; Renee Anderson; Michael Chang; Anna Sasaki; Kenneth Flora; Arthur Vandenbark; Suzanne H Mitchell; Jennifer M Loftis; William F Hoffman; Marilyn Huckans
Journal:  J Neurovirol       Date:  2018-10-08       Impact factor: 2.643

Review 9.  Neuroimaging Findings in Chronic Hepatitis C Virus Infection: Correlation with Neurocognitive and Neuropsychiatric Manifestations.

Authors:  Matteo Tagliapietra; Salvatore Monaco
Journal:  Int J Mol Sci       Date:  2020-04-02       Impact factor: 5.923

10.  HIV and disability: a pilot study exploring the use of the Assessment of Motor and Process Skills to measure daily life performance.

Authors:  Brenda Merritt; Jacqueline Gahagan; Anders Kottorp
Journal:  J Int AIDS Soc       Date:  2013-01-21       Impact factor: 5.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.